Literature DB >> 19763889

Regulatory T cells and immune tolerance to tumors.

Xuefang Cao1.   

Abstract

Immune cells infiltrate tumors and make up a significant component of the multicellular cancer micro-environment, yet the immune system often fails to prevent tumor formation and progression. One explanation for this paradox is the presence of tolerance-promoting regulatory T cells (Tregs) that counteract antitumor immune cells. Tregs were known to be essential for maintaining self-tolerance. Recently, Tregs have been found to promote tolerance to tumors in mouse models. Moreover, Treg infiltration in human tumors and malignant ascites is associated with worse clinical outcomes for various types of cancers. As many reviews have discussed the development and function of Tregs, this review focuses on the cellular and molecular mechanisms by which Tregs influence antitumor immune responses, and also discusses how these mechanisms might be exploited to develop innovative immune-based approaches that can improve cancer therapy.

Entities:  

Mesh：

Year:  2010        PMID： 19763889     DOI： 10.1007/s12026-009-8124-7

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  106 in total

1.  Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity.

Authors:  Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Med       Date:  2002-07-29       Impact factor: 53.440

2.  Donor lymphocyte infusion induces long-term donor-specific cardiac xenograft survival through activation of recipient double-negative regulatory T cells.

Authors:  Wenhao Chen; Dejun Zhou; Jose R Torrealba; Thomas K Waddell; David Grant; Li Zhang
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

4.  Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression.

Authors:  Cecilia Oderup; Lukas Cederbom; Anna Makowska; Corrado M Cilio; Fredrik Ivars
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

5.  A critical function for type I interferons in cancer immunoediting.

Authors:  Gavin P Dunn; Allen T Bruce; Kathleen C F Sheehan; Vijay Shankaran; Ravindra Uppaluri; Jack D Bui; Mark S Diamond; Catherine M Koebel; Cora Arthur; J Michael White; Robert D Schreiber
Journal:  Nat Immunol       Date:  2005-06-12       Impact factor: 25.606

6.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.

Authors:  Hiroshi Nagai; Tatsuya Horikawa; Isao Hara; Atsushi Fukunaga; Shuntaro Oniki; Masahiro Oka; Chikako Nishigori; Masamitsu Ichihashi
Journal:  Exp Dermatol       Date:  2004-10       Impact factor: 3.960

9.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

Authors:  Xuefang Cao; Sheng F Cai; Todd A Fehniger; Jiling Song; Lynne I Collins; David R Piwnica-Worms; Timothy J Ley
Journal:  Immunity       Date:  2007-10-04       Impact factor: 31.745

10.  Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.

Authors:  François Ghiringhelli; Pierre E Puig; Stephan Roux; Arnaud Parcellier; Elise Schmitt; Eric Solary; Guido Kroemer; François Martin; Bruno Chauffert; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307
View more
  28 in total

1.  Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.

Authors:  Byung-Su Kim; Hidekazu Nishikii; Jeanette Baker; Antonio Pierini; Dominik Schneidawind; Yuqiong Pan; Andreas Beilhack; Chung-Gyu Park; Robert S Negrin
Journal:  Blood       Date:  2015-06-10       Impact factor: 22.113

2.  Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Authors:  Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 3.  Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.

Authors:  Trisha A Rettig; Julie N Harbin; Adelaide Harrington; Leonie Dohmen; Sherry D Fleming
Journal:  Clin Immunol       Date:  2015-07-02       Impact factor: 3.969

4.  Interleukin-35 Limits Anti-Tumor Immunity.

Authors:  Meghan E Turnis; Deepali V Sawant; Andrea L Szymczak-Workman; Lawrence P Andrews; Greg M Delgoffe; Hiroshi Yano; Amy J Beres; Peter Vogel; Creg J Workman; Dario A A Vignali
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

5.  Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.

Authors:  Jena D French; Zachary J Weber; Deborah L Fretwell; Sherif Said; Joshua P Klopper; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2010-03-05       Impact factor: 5.958

6.  Interferon-Gamma Receptor Signaling Plays an Important Role in Restraining Murine Ovarian Tumor Progression.

Authors:  Guanglin Bian; Nicholas D Leigh; Wei Du; Lei Zhang; Li Li; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2016-04-28

Review 7.  Current understanding of the tumor microenvironment of laryngeal dysplasia and progression to invasive cancer.

Authors:  Sumita Trivedi; Clark A Rosen; Robert L Ferris
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2016-04       Impact factor: 2.064

8.  Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21.

Authors:  Hadiseh Samiei; Bizhan Sadighi-Moghaddam; Saeed Mohammadi; Abdolsamad Gharavi; Sara Abdolmaleki; Ayyoob Khosravi; Parviz Kokhaei; Hadi Bazzazi; Ali Memarian
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

9.  Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts.

Authors:  Sankar Bhattacharyya; Dewan Md Sakib Hossain; Suchismita Mohanty; Gouri Sankar Sen; Sreya Chattopadhyay; Shuvomoy Banerjee; Juni Chakraborty; Kaushik Das; Diptendra Sarkar; Tanya Das; Gaurisankar Sa
Journal:  Cell Mol Immunol       Date:  2010-03-22       Impact factor: 11.530

10.  PD-1 regulates extrathymic regulatory T-cell differentiation.

Authors:  Xiufen Chen; Dominick Fosco; Douglas E Kline; Liping Meng; Saki Nishi; Peter A Savage; Justin Kline
Journal:  Eur J Immunol       Date:  2014-08-18       Impact factor: 5.532
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.